Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 6/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4658092 | 0.83 | TSHR (0.49) | KAT2BTSHRCYP3A4RAB9ANPC1 | |
| SCHEMBL6907821 | 0.83 | TSHR (0.60) | KAT2BTSHRCYP3A4TAAR1ACHE | |
| SCHEMBL3515439 | 0.81 | ATM (0.56) | KAT2B | |
| SCHEMBL4658987 | 0.80 | NPC1 (0.49) | TSHRCYP3A4RAB9AMEN1KMT2A | |
| SCHEMBL4657144 | 0.80 | TSHR (0.49) | KAT2BTSHRCYP3A4RAB9AACHE | |
| SCHEMBL27780345 | 0.80 | TSHR (0.56) | KAT2BTSHRCYP3A4RAB9AMEN1 | |
| SCHEMBL4966586 | 0.80 | TSHR (0.56) | KAT2BTSHRCYP3A4ACHE | |
| SCHEMBL3633384 | 0.80 | KAT2B (0.43) | KAT2BTSHRCYP3A4 | |
| SCHEMBL7193090 | 0.79 | TSHR (0.64) | KAT2BTSHRCYP3A4RAB9AMEN1 | |
| SCHEMBL27599498 | 0.78 | TSHR (0.62) | KAT2BTSHRCYP3A4RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | KAT2B 924/4885TSHR 4209/4885CYP3A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.